{"id":63968,"date":"2024-04-04T13:00:00","date_gmt":"2024-04-04T13:00:00","guid":{"rendered":"http:\/\/pr.asianetpakistan.com\/?guid=f58e518d2dc8e3cb5f5a4bb0e39c23f3"},"modified":"2024-04-04T13:00:00","modified_gmt":"2024-04-04T13:00:00","slug":"participants-in-nigeria-vaccinated-in-first-ever-phase-2-lassa-fever-vaccine-clinical-trial-sponsored-by-iavi","status":"publish","type":"post","link":"https:\/\/southafricagazette.com\/participants-in-nigeria-vaccinated-in-first-ever-phase-2-lassa-fever-vaccine-clinical-trial-sponsored-by-iavi\/","title":{"rendered":"Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI"},"content":{"rendered":"
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate<\/i><\/p>\n
Key takeaways:<\/strong><\/i><\/p>\n NEW YORK, NY \/ ACCESSWIRE \/ April 4, 2024 \/<\/strong> Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105\/PREVAIL15<\/a>) is funded by CEPI<\/a>, an innovative global partnership working to accelerate the development of vaccines against epidemic and pandemic threats.<\/p>\n\n